The interaction with GSK goes deeper, with Novartis and GSK announcing a merger of their OTC divisions to create a new joint venture which will be number one in the sector. This mirrors an earlier ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

While generics may dominate due to cost advantages and meeting needs of a developing economy, there is a growing thrust ...

GSK cuts 2024 vaccine sales forecast for second time this year Strong specialty medicines offset lower vaccine sales - CEO Q3 EPS beats market expectations Shares down 3.9% at 0958 GMT Oct 30 ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

Private equity investors GHO Capital Partners and Ampersand Capital Partners have announced a merger agreement for the ...

The winner will be announced Wednesday evening at The American Lawyer's Industry Awards. These attorneys have been named ...

Welcome to today's call and webcast. The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to Slide 2. This is the usual safe harbor ...

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...

GlaxoSmithKline was formerly called GlaxoWelcome before its merger with U.S. pharmaceutical company SmithKline Beecham in 2000. The combination has made GlaxoSmithKline the 6th largest ...